Loading
NOTCH1 (Neurogenic locus notch homolog protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Head and neck squamous cell carcinoma and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Involved in the maturation of both CD4(+) and CD8(+) cells in the thymus. Important for follicular differentiation and possibly cell fate selection within the follicle. Location: Cell membrane; Late endosome membrane; Nucleus (UniProt). Locus 9q34.3 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Small-cell lung cancer | 13-25% | Inactivating mutation | cBioPortal: NOTCH1 mutated in 16 of 120, 13.3%, in sclc_ucologne_2015. Inactivating mutations across the NOTCH family were found in 25% of the sequenced tumours, and activating Notch signalling in a mouse model strikingly reduced tumour number, extended survival and abolished neuroendocrine gene expression (George 2015). | cBioPortal (TCGA) |
| Triple-negative breast cancer | 5-9% | Activating rearrangement, PEST-domain mutation or amplification | NOTCH1 and NOTCH2 rearrangements causing constitutive activation in 6 of 66 TNBCs, 9%, and in no other solid tumour type (Stoeck 2014); PEST-domain mutations of NOTCH1, NOTCH2 and NOTCH3 and focal NOTCH2/NOTCH3 amplifications significantly enriched in the TNBC subset of TCGA (Wang 2015); cBioPortal: NOTCH1 mutation in 16 of 299, 5.4%, in brca_metabric and 9 of 176, 5.1%, in breast_msk_2018; NOTCH2 amplification in 21 of 119, 17.6%, in brca_tcga_pan_can_atlas_2018. | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"NOTCH1" OR ABSTRACT:"NOTCH1" OR TITLE:"notch receptor 1" OR ABSTRACT:"notch receptor 1" OR TITLE:"Neurogenic locus notch homolog protein 1" OR ABSTRACT:"Neurogenic locus notch homolog protein 1" OR TITLE:"TAN1" OR ABSTRACT:"TAN1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NOTCH1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/notch1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/notch1.json. Licence CC BY-NC 4.0.